Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TRIUMPH-1

TRIUMPH-1

Retatrutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
obesity
Official title
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2023-07 → 2026-04
Participants
2335
Duration
80 weeks
Registry
NCT05929066

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
retatrutide 4 mgobesity80584−19.0 % vs −2.2 %
Δ −16.8 pp
−17.6 % vs −3.9 %
Δ −13.7 pp
—4.1 vs 4.6—28.6 vs 14.810.6 vs 4.87.7 vs 5.5−7.6 vs −1.9verified
retatrutide 9 mgobesity80584−25.9 % vs −2.2 %
Δ −23.7 pp
−23.7 % vs −3.9 %
Δ −19.8 pp
—6.5 vs 4.6—38.4 vs 14.822.8 vs 4.87.7 vs 5.5−9.8 vs −1.9verified
retatrutide 12 mgobesity80584−28.3 % vs −2.2 %
Δ −26.1 pp
−25.0 % vs −3.9 %
Δ −21.1 pp
—11.2 vs 4.6—42.4 vs 14.825.3 vs 4.810.5 vs 5.5−10.4 vs −1.9verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (21)
  • retatrutide 4 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
    The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
  • retatrutide 4 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
    −17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
  • retatrutide 4 mg · ae_dc · Table 3
    Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
  • retatrutide 4 mg · nausea · Table 3
    Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
  • retatrutide 4 mg · vomiting · Table 3
    Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
  • retatrutide 4 mg · sae · Table 3
    Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
  • retatrutide 4 mg · sbp · Table 2 (continued)
    Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
  • retatrutide 9 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
    The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
  • retatrutide 9 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
    −17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
  • retatrutide 9 mg · ae_dc · Table 3
    Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
  • retatrutide 9 mg · nausea · Table 3
    Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
  • retatrutide 9 mg · vomiting · Table 3
    Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
  • retatrutide 9 mg · sae · Table 3
    Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
  • retatrutide 9 mg · sbp · Table 2 (continued)
    Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
  • retatrutide 12 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
    The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
  • retatrutide 12 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
    −17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
  • retatrutide 12 mg · ae_dc · Table 3
    Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
  • retatrutide 12 mg · nausea · Table 3
    Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
  • retatrutide 12 mg · vomiting · Table 3
    Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
  • retatrutide 12 mg · sae · Table 3
    Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
  • retatrutide 12 mg · sbp · Table 2 (continued)
    Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TRIUMPH-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.